The Clinton Foundation has announced agreements with Matrix (subsidiary of Mylan) and Pfizer to bring the cost of second-line antiretrovirals (ARVs) to under US$500 per person annually and reduce the cost of a key tuberculosis (TB) drug to $1 per dose.

"Today's announcement will help ensure we can sustain treatment over a lifetime and better treat patients with both HIV and TB, two key steps in turning the tide of the global HIV/AIDS pandemic," Clinton said, according to a press release on the Clinton Foundation website.

For more information you can use the following links:
http://www.clintonfoundation.org/
http://www.plusnews.org/Report.aspx?Reportid=85623